Cargando…
Creatine kinase levels in asthma patients receiving interleukin-5 therapy
Autores principales: | Kavanagh, Grace A., Casey, Deborah, Cusack, Ruth P., Plant, Barry J., Murphy, Desmond M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478696/ https://www.ncbi.nlm.nih.gov/pubmed/37013792 http://dx.doi.org/10.1177/17534666221122475 |
Ejemplares similares
-
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy
por: O’Reilly, Emily, et al.
Publicado: (2022) -
Characteristics of abnormal serum creatine kinase-MB levels in children with COVID-19
por: Wang, Juan-Juan, et al.
Publicado: (2021) -
The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
por: Ibrahim, H., et al.
Publicado: (2019) -
Hypokalemia- induced myopathy and massive creatine kinase elevation as first manifestation of Conn's syndrome
por: Olt, Serdar, et al.
Publicado: (2013) -
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)